Weekly injection trial aims to stop dangerous bleeds in rare blood disorder
NCT ID NCT05345197
Summary
This study is testing whether regular injections of emicizumab can prevent bleeding episodes in adults with acquired hemophilia A, a rare condition where the immune system attacks blood clotting factors. 51 participants will receive weekly injections alongside other immune-suppressing medications. Researchers will measure how many serious bleeds occur during 12 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bleeding and Clotting Disorders Institute
Peoria, Illinois, 61614, United States
-
Emory University
Atlanta, Georgia, 30308, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Hemophilia Center of Western Pennsylvania
Pittsburgh, Pennsylvania, 15213, United States
-
Indiana Hemophilia and Thrombosis Center, Inc.
Indianapolis, Indiana, 46260, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Penn Blood Disorders Program, Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Tulane University
New Orleans, Louisiana, 70112-2632, United States
-
UCSD Hemophilia and Thrombosis Treatment Center
San Diego, California, 92121, United States
-
UVA Comprehensive Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
Versiti Inc.
Milwaukee, Wisconsin, 53226, United States
-
Washington Center for Bleeding Disorders
Seattle, Washington, 98101, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.